Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Modelo predictivo del riesgo de infección y rechazo después del trasplante renal basado en la combinadición de parámetros clínicos y biomarcadores.

IP: Francesc Moreso Mateos
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa, Romina Dieli Crimi, Nestor Gabriel Toapanta Gaibor, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI18/01832
Duration: 01/01/2019 - 31/12/2022

Relación entre los niveles de tacrolimus y/o dosis de micofenolato y la modulación de los genes de rechazo en biopsias de seguimiento del aloinjerto renal

IP: Daniel Serón Micas
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI18/01704
Duration: 01/01/2019 - 31/12/2021

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Promoting regeneration versus tubulointerstitial fibrosis in progressive renal disease: Novel molecular pathways

IP: Promoting regeneration versus tubulointerstitial fibrosis in progressive renal disease: Novel molecular pathways
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO-2012-01
Duration: 06/10/2012 - 05/10/2014

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Jorge Pamias Romero

Jorge Pamias Romero

New Technologies and Craniofacial Microsurgery
Read more
Olga Luengo Sanchez

Olga Luengo Sanchez

Systemic Diseases
Read more
Anna Salo Rovira

Anna Salo Rovira

Research technician
Childhood Cancer and Blood Disorders
Read more
Estefania De la Torre Villaescusa

Estefania De la Torre Villaescusa

Head of unit
Teaching Unit
Internal Strategy Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.